Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis previously treated with a JAK inhibitor (MOMENTUM): an updated analysis of an international, double-blind, randomised phase 3 study

Data from an updated analysis of the phase 3 MOMENTUM trial showed that momelotinib is associated with durable symptom, spleen, and anemia benefits; late responses after week 24; and favorable safety through week 48 among patients with myelofibrosis, compared with danazol. Total Symptom Score responders by week 48 included 61% of evaluable patients in the momelotinib group who continued and 59% in the danazol group who crossed over, including most week 24 responders plus new responders after week 24.